Ipsen (IPSEY) News Today → My system predicted the BA collapse – now it’s issuing an AI warning (From Chaikin Analytics) (Ad) Free IPSEY Stock Alerts $33.52 +1.29 (+4.00%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartDividendHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 1:24 AM | americanbankingnews.comIpsen S.A. (OTCMKTS:IPSEY) Sees Large Growth in Short InterestMay 7, 2024 | globenewswire.comIpsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General MeetingMay 7, 2024 | americanbankingnews.comIpsen (OTCMKTS:IPSEY) Share Price Passes Above 200 Day Moving Average of $28.98May 2, 2024 | finance.yahoo.comIpsen appoints Keira Driansky as EVP, President of North AmericaApril 24, 2024 | msn.comIpsen S.A. reports Q1 results; reaffirms full-year guidanceApril 24, 2024 | markets.businessinsider.comIpsen Q1 Total-sales Up 13.3% At CER; Confirms 2024 Financial GuidanceApril 24, 2024 | finance.yahoo.comIpsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidanceApril 23, 2024 | finanznachrichten.deIpsen Pharma: Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesApril 22, 2024 | markets.businessinsider.comIpsen, Skyhawk Therapeutics To Develop RNA-Modulating Molecules For Rare Neurological DisordersApril 17, 2024 | finance.yahoo.comIpsen publishes its 2023 Universal Registration DocumentApril 5, 2024 | seekingalpha.comIpsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For InvestorsApril 2, 2024 | finance.yahoo.comMarengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with IpsenFebruary 15, 2024 | globenewswire.comIpsen S.A. publishes its 2023 Consolidated Financial StatementsFebruary 14, 2024 | financialpost.comIpsen's Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDAFebruary 13, 2024 | finance.yahoo.comIpsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDAFebruary 13, 2024 | msn.comIpsen gets FDA approval for pancreatic cancer drug regimenFebruary 8, 2024 | marketwatch.comIpsen Shares Fall After Forecast of Lower MarginFebruary 8, 2024 | markets.businessinsider.comBuilding on solid FY 2023 results, Ipsen anticipates four launches in 2024February 8, 2024 | markets.businessinsider.comIpsen FY23 Profit Flat, Sales Rise; Sees Growth In FY24, Backs Mid-term ViewFebruary 8, 2024 | msn.comIpsen S.A. Non-GAAP EPS of €9.15, revenue of €3.13B; initiates FY24 outlookFebruary 6, 2024 | finance.yahoo.comIpsen - Monthly information relative to the total number of voting rights and shares composing the share capitalJanuary 31, 2024 | markets.businessinsider.comBiotech Stocks Facing FDA Decision In February 2024January 22, 2024 | finanznachrichten.deIpsen Pharma: Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024January 22, 2024 | finance.yahoo.comLatest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024December 7, 2023 | markets.businessinsider.comIpsen : FDA Grants Priority Review To Elafibranor NDA For Rare Cholestatic Liver Disease TreatmentDecember 7, 2023 | finance.yahoo.comCapital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlookNovember 13, 2023 | markets.businessinsider.comIpsen Says Health Canada Approved Bylvay To Treat Pruritus Due To PFICNovember 13, 2023 | finance.yahoo.comIpsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)October 26, 2023 | nasdaq.comIpsen 9-month Sales UpOctober 23, 2023 | markets.businessinsider.comIpsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndromeOctober 3, 2023 | finanznachrichten.deIpsen Pharma: Ipsen updates on QM-1114 regulatory processOctober 3, 2023 | finance.yahoo.comIpsen updates on QM-1114 regulatory processSeptember 28, 2023 | fortune.comLaura IpsenSeptember 17, 2023 | msn.comIpsen celebrates 75 years of its location in Cherry ValleySeptember 1, 2023 | finance.yahoo.comIpsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle HuguetAugust 21, 2023 | msn.comExelixis lead product hits main goal in Phase 3 prostate cancer trialAugust 17, 2023 | msn.comUS FDA approves French drugmaker Ipsen's rare bone disorder drugAugust 16, 2023 | bloomberg.comUS Approves Ipsen’s Therapy for Rare Bone DiseaseAugust 16, 2023 | usnews.comUS FDA Approves Ipsen's Rare Bone Disorder DrugAugust 16, 2023 | finance.yahoo.comUS FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressivaJuly 28, 2023 | finanznachrichten.deIpsen Pharma: Ipsen delivers solid H1 2023 results and upgrades its full-year guidanceJuly 27, 2023 | marketwatch.comIpsen Shares Rise After It Upgrades 2023 OutlookJuly 27, 2023 | finance.yahoo.comIpsen delivers solid H1 2023 results and upgrades its full-year guidanceJuly 24, 2023 | finance.yahoo.comIpsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023July 21, 2023 | marketwatch.comIpsen's Bylvay for Alagille Syndrome Recommended for Approval by EU AgencyJuly 21, 2023 | finance.yahoo.comIpsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndromeJuly 19, 2023 | finanznachrichten.deIpsen Pharma: Ipsen announces European Commission decision on palovarotene for the treatment of FOPJuly 19, 2023 | uk.finance.yahoo.comIpsen announces European Commission decision on palovarotene for the treatment of FOPJune 30, 2023 | markets.businessinsider.comGenfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-ClassJune 30, 2023 | msn.comIpsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients Get Ipsen News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden FINISHED On June 13th? (Ad)Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered. Click here now to see his shocking evidence. IPSEY Media Mentions By Week IPSEY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPSEY News Sentiment▼0.130.56▲Average Medical News Sentiment IPSEY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPSEY Articles This Week▼21▲IPSEY Articles Average Week Get Ipsen News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSEY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Response Genetics News 1933 Industries News 4Front Ventures News AB Science News Aclarion News Acreage News Acreage News ADM Tronics Unlimited News Aleafia Health News Algernon Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:IPSEY) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe only AI company you should be looking atBehind the MarketsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ipsen S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
